Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment.

Journal Article (Journal Article)

PURPOSE: Ductal carcinoma in situ (DCIS), a nonobligate precursor of breast cancer, is often aggressively managed with multimodal therapy. However, there is limited research on patients' preferences for trade-offs among treatment-related outcomes such as breast appearance, side effects, and future cancer risk. We sought to investigate whether women consider treatment features aside from cancer risk when making treatment choices for ductal carcinoma in situ and if so, to what degree other features influence these decisions. METHODS: A discrete choice experiment was administered to participants in a comprehensive cancer screening mammography clinic. The experimental design was used to generate constructed health profiles resulting from different management strategies. Health profiles were defined by breast appearance, severity of infection within the first year, chronic pain, hot flashes, and risk of developing or dying from breast cancer within 10 years. RESULTS: One hundred ninety-four women without a personal history of breast cancer completed the choice task. Across 10 choice questions, 29% always selected the health profile with a lower risk of invasive breast cancer (ie, dominated on cancer risk), regardless of the effects of treatment. For nonrisk dominators, breast cancer risk remained the most important factor but was closely followed by chronic pain (24% [95% CI, 20 to 28]) and infection (22% [95% CI, 18 to 25]). Depending on treatment outcomes, the tolerable increase in breast cancer risk was as high as 3.4%. CONCLUSION: Most women were willing to make some trade-offs between invasive cancer risk and treatment-related outcomes. Our findings highlight the importance of shared decision-making weighing risks and benefits between patient and provider management of low-risk disease.

Full Text

Duke Authors

Cited Authors

  • Chapman, BM; Yang, J-C; Gonzalez, JM; Havrilesky, L; Reed, SD; Hwang, ES

Published Date

  • March 12, 2021

Published In

  • Jco Oncol Pract

Start / End Page

  • OP2000614 -

PubMed ID

  • 33710917

Electronic International Standard Serial Number (EISSN)

  • 2688-1535

Digital Object Identifier (DOI)

  • 10.1200/OP.20.00614


  • eng

Conference Location

  • United States